Clinical Manifestations of Allergic Diseases: Drug Hypersensitivity

  • Benno Schnyder
  • Werner J. Pichler
Part of the Allergy Frontiers book series (ALLERGY, volume 4)

Drug allergies are those adverse drug reactions that are mediated by the specific immune system. Primary sensitization may involve T-cells alone or both T and B-cells with consecutive production of drug specific antibodies of different isotypes. It is mostly asymptomatic. However, there is evidence that primary sensitization may be induced not only by drug derived hapten-carrier-compounds, but also by cross-reactive allergens (e.g. viral infect, contact allergen etc.). Thus, an immune mechanism should also be considered in the case of reactions occurring on primary exposure to the causative drug.

The elicitation phase (or secondary response) can be divided into 4 categories corresponding to the type I–IV reactions described by Gell & Coombs. The vast majority of true drug allergies are thought to be either Ig-E (Type I) or T-lymphocyte-mediated (Type IV).

Drug allergy can cause a variety of diseases involving the skin, liver, kidney, lungs, and other organs. There is no single standardized diagnostic test that is able to confirm the immune mediated mechanism and identify the causative drug. Therefore, immune mediated drug hypersensitivity reactions and their causative drugs have to be recognized clinically by the constellation of exposure, timing, and pattern of organ manifestation. The diagnostic value of additional allergologic investigations is limited and their negative predictive value is not sufficient to exclude a drug allergy in the case of a suggestive history. Allergologic investigations comprise skin tests with immediate and late readings, the basophil activation test (BAT), and the lymphocyte transformation test (LTT). Provocation tests in order to identify the culprit drug are risky. The main target of allergologic investigations after a hypersensitivity reaction should be to enable doctors to prescribe further treatment with an appropriate risk/benefit ratio. Thus, such investigations may be reserved for finding an alternative drug therapy in situations where the incriminated drug(s) cannot easily be replaced.


Toxic Epidermal Necrolysis Drug Allergy Drug Hypersensitivity Basophil Activation Test Acute Generalize Exanthematous Pustulosis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Gomes ER, Demoly P. Epidemiology of hypersensitivity drug reactions. Curr Opin Allergy Clin Immunol 2005; 5:309–316PubMedCrossRefGoogle Scholar
  2. 2.
    Rawlins M, Thompson W. Mechanisms of adverse drug reactions. In: Davies D, ed. Textbook of adverse drug reactions. New York: Oxford University Press; 1991, pp. 18–45Google Scholar
  3. 3.
    Naisbitt DJ, Grodon SF, Pirmohamed M, Park BK. Immunological principles of adverse drug reactions: the initiation and propagation of immune responses elicited by drug treatment. Drug Saf 2000; 23:483–507PubMedCrossRefGoogle Scholar
  4. 4.
    Gerber BO, Pichler WJ. Cellular mechanisms of T cell mediated drug hypersensitivity. Curr Opin Immunol 2004; 16:732–737PubMedCrossRefGoogle Scholar
  5. 5.
    Aster RH. Drug-induced immune cytopenias. Toxicology 2005 Apr 15;209(2):149–153CrossRefGoogle Scholar
  6. 6.
    Warkentin TE, Levine MN, Hirsh J, Horsewood PD, Roberts S, Gen M, Kleton JG. NJEM, heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med 2007; 356:891–893PubMedCrossRefGoogle Scholar
  7. 7.
    Riley R, Leeder J. In vitro analysis of metabolic predisposition to drug hypersensitivity reactions. Clin Exp Immunol 1995; 99:1–6PubMedCrossRefGoogle Scholar
  8. 8.
    Schnyder B, Mauri-Hellweg D, Zanni M, Bettens F, Pichler WJ. Direct, MHC-dependent presentation of the drug sulfamethoxazole to human alpha-beta T cell clones. J Clin Invest 1997; 100:136–141PubMedCrossRefGoogle Scholar
  9. 9.
    Zanni MP, von Greyerz S, Schnyder B, Brander KA, Frutig K, Hari Y, Valitutti S, Pichler WJ. HLA-restricted, processing- and metabolism-independent pathway of drug recognition by human alpha beta T lymphocytes. J Clin Invest 1998; 102:1591–1598PubMedCrossRefGoogle Scholar
  10. 10.
    Pichler WJ. Delayed drug hypersensitivity reactions. Ann Intern Med 2003 Oct 21;139(8):683–693Google Scholar
  11. 11.
    Clark RA, Chong B, Mirchandani N, Brinster NK, Yamakana K, Dowgiert RK, Kupper TS. The vast majority of CLA+ T cells are resident in normal skin. J Immunol 2006; 176:4431–4439PubMedGoogle Scholar
  12. 12.
    Schaerli P, Moser B. Chemokines: control of primary and memory T-cell traffic. Immunol Res 2005; 31:57–74PubMedCrossRefGoogle Scholar
  13. 13.
    Ellis AK, Day JH. Diagnosis and management of anaphylaxis. Can Med Assoc J 2003; 169:307–311Google Scholar
  14. 14.
    Mertes PM, Laxenaire MC. Allergic reactions occurring during anaesthesia. Eur J Anaesthesiol 2002; 19:240–262PubMedGoogle Scholar
  15. 15.
    Weiss ME, Adkinson NF. Immediate hypersensitivity reactions to beta-lactam antibiotics. Ann Int Med 1987; 107:204–215Google Scholar
  16. 16.
    Ebo DG, Fisher MM, Hagendorens MM, Bridts CH, Stevens WJ. Anaphylaxis during anaesthesia: diagnostic approach. Allergy 2007; 62:471–487PubMedCrossRefGoogle Scholar
  17. 17.
    Torres MJ, Romano A, Mayorga C, Moya MC, Guzman AE, Reche M, Juarez C, Blanca M. Diagnostic evaluation of a large group of patients with immediate allergy to penicillins: the role of skin testing. Allergy 2001 Sept; 56(9):850–856PubMedCrossRefGoogle Scholar
  18. 18.
    Fiszenson-Albala F, Auzerie V, Mahe E, Farinotti R, Durand-Stocco C, Crickx B, Descamps V. A 6-month prospective survey of cutaneous drug reactions in a hospital setting. Br J Dermatol 2003 Nov; 149(5):1018–1022PubMedCrossRefGoogle Scholar
  19. 19.
    Lee AY. Fixed drug eruptions. Incidence, recognition, and avoidance. Am J Clin Dermatol 2000 Sept–Oct; 1(5):277–285PubMedCrossRefGoogle Scholar
  20. 20.
    Wolf R, Orion E, Matz H. The baboon syndrome or intertriginous drug eruption: a report of 11 cases and a second look at its pathomechanism. Dermatol Online J 2003; 3(9):2Google Scholar
  21. 21.
    Hausermann P, Harr T, Bircher AJ. Baboon syndrome resulting from systemic drugs: is there strife between SDRIFE and allergic contact dermatitis syndrome? Contact Dermatitis 2004 Nov–Dec; 51:297–310PubMedCrossRefGoogle Scholar
  22. 22.
    Britschgi M, Steiner UC, Schmid S, Depta JP, Senti G, Bircher A, Burkhart C, Yawalkar N, Pichler WJ, et al. T-cell involvement in drug-induced acute generalized exanthematous pustu-losis. J Clin Invest 2001; 107:1433–1441PubMedCrossRefGoogle Scholar
  23. 23.
    Roujeau J, Bioulac-Sage P, Bourseau C. Acute generalized exanthematous pustulosis: analysis of 63 cases. Arch Dermatol 1991; 127:1333–1338PubMedCrossRefGoogle Scholar
  24. 24.
    Keller M, Spanou Z, Schaerli P, Britschgi M, Yawalkar N, Seitz M, Villiger PM, Pichler WJ. T cell-regulated neutrophilic inflammation in autoinflammatory diseases. J Immunol 2005; 175:7678–7686PubMedGoogle Scholar
  25. 25.
    Roujeau JC, Stern RS. Severe adverse cutaneous reactions to drugs. N Engl J Med 1994; 331:1272–1285PubMedCrossRefGoogle Scholar
  26. 26.
    French LE. Toxic epidermal necrolysis and Stevens Johnson syndrome: our current understanding. Allergol Int 2006; 55:9–16PubMedCrossRefGoogle Scholar
  27. 27.
    Knowles SR, Shapiro LE, Shear NH. Anticonvulsant hypersensitivity syndrome: incidence, prevention and management. Drug Saf 1999; 21:489–501PubMedCrossRefGoogle Scholar
  28. 28.
    Shiohara T, Inaoka M, Kano Y. Drug induced hypersensitivity syndrome (DIHS): a reaction induced by a complex interplay among herpesvirus and antiviral and antidrug immune responses. Allergol Int 2006; 55:1–8PubMedCrossRefGoogle Scholar
  29. 29.
    Sarzi-Puttini P, Atzeni F, Capsoni F, Lubrano E, Doria A. Drug-induced lupus erythematosus. Autoimmunity 2005 Nov; 38(7):507–518PubMedCrossRefGoogle Scholar
  30. 30.
    Doyle MK, Cuellar ML. Drug-induced vasculitis. Expert Opin Drug Saf 2003; 2:401–409PubMedCrossRefGoogle Scholar
  31. 31.
    Pruss A, Salama A, Ahrens N, Hansen A, Kiesewetter H, Koscielny J, Dorner T. Immune hemolysis-serological and clinical aspects. Clin Exp Med 2003 Sept; 3(2):55–64.PubMedCrossRefGoogle Scholar
  32. 32.
    Van den Bernt PM, Meyboom RH, Egberts AC. Drug-induced immune thrombocytopenia. Drug Saf 2004; 27(15):1243–1252CrossRefGoogle Scholar
  33. 33.
    Greinacher A, Eichler P, Lubenow N, Kiefel V. Drug-induced and drug-dependent immune thrombocytopenias. Rev Clin Exp Hematol 2001 Sept; 5(3):166–200PubMedCrossRefGoogle Scholar
  34. 34.
    Barbaud A, Concalo M, Bruynzeel D, Bircher A. European Society of Contact Dermatitis. Guidelines for performing skin tests with drugs in the investigation of cutaneous adverse drug reactions. Contact Dermatitis 2001 Dec; 45(6):321–328PubMedCrossRefGoogle Scholar
  35. 35.
    Evans C, Tippins E. Emergency treatment of anaphylaxis. Accid Emerg Nurs 2005 Oct; 13(4):232–237. Epub 2005 Sept 21PubMedCrossRefGoogle Scholar
  36. 36.
    Ewan PW, Anaphylaxis. Br Med J 1998; 316:1442–1445Google Scholar
  37. 37.
    Ghislain PD, Roujeau JC. Treatment of severe drug reactions: Stevens-Johnson syndrome, toxic epidermal necrolysis and hypersensitivity syndrome. Dermatol Online J 2002 June; 8:5PubMedGoogle Scholar
  38. 38.
    Karaun SH, Jonkman MF. Dexamethasone pulse therapy for Stevens-Johnson syndrome/toxic epidermal necrolysis. Acta Derm Venereol 2007; 87(2):144–148CrossRefGoogle Scholar
  39. 39.
    Mittmann N, Chan BC, Knowles S, Shear NH. IVIG for the treatment of toxic epidermal necrolysis. Skin Ther Lett 2007 Feb; 12(1):7–9Google Scholar
  40. 40.
    Kelkar PS, Li JT. Cephalosporin allergy. N Engl J Med 2001; 345:804–809PubMedCrossRefGoogle Scholar
  41. 41.
    Sodhi M, Axtell SS, Callahan J, Shekar R. Is it safe to use carbapenems in patients of allergy to penicillin? J Antimicrob Chemother 2004; 54:1155–1157PubMedCrossRefGoogle Scholar
  42. 42.
    Mauri-Hellweg D, Zann M, Frei E, Bettens F, Brander C, Mauri D, Padovan E, Weltzin HU, Pichler WJ. Cross-reactivity of T cell lines and clones to beta-lactam antibiotics. J Immunol 1996; 157:1071–1079PubMedGoogle Scholar
  43. 43.
    von Greyerz S, Zanni MP, Frutig K, Schnyder B, Burkhart C, Pichler WJ. Interaction of sulfonamide derivatives with the TCR of sulfamethoxazole-specific human αß+ T cell clones. J Immunol 1999; 162:595–602Google Scholar
  44. 44.
    Schmid DA, Depta JP, Lüthi M, Pichler WJ. Transfection of drug-specific T-cell receptors into hybridoma cells: tools to monitor drug interaction with T-cell receptors and evaluate cross-reactivity to related compounds. Mol Pharmacol 2006 July; 70(1):356–365PubMedGoogle Scholar
  45. 45.
    Brackett CC. Likelihood and mechanisms of cross-allergenicity between sulfonamide antibiotics and other drugs containing a sulfonamide functional group. Pharmacotherapy 2004; 24(7):856–870PubMedCrossRefGoogle Scholar
  46. 46.
    Strom BL, Schinnar R, Apter AJ, et al. Absence of cross-reactivity between sulfonamide antibiotics and sulfonamide nonantibiotics. N Engl J Med 2003; 349:1628–1635PubMedCrossRefGoogle Scholar
  47. 47.
    Lerch M, Keller M, Britschgi M, Kanny G, Tache V, Schmid DA, Beeler A, Gerber BO, Luethi M, Bircher AJ, Christiansen C, Pichler WJ. Cross-reactivity patterns of T cells specific for iodinated contrast media. J Allergy Clin Immunol 2007 June; 119(6):1529–1536. Epub 2007PubMedCrossRefGoogle Scholar
  48. 48.
    Thyssen JP, Menné T, Elberling J, Plaschke P, Johansen JD. Hypersensitivity to local anaesthetics—update and proposal of evaluation algorithm.Contact Dermatitis 2008 Aug; 59(2):69–78PubMedCrossRefGoogle Scholar
  49. 49.
    Lutz EM, El-Azhary AR. Allergic contact dermatitis due to topical application of corticosteroids: review and clinical implications. Mayo Clin Proc 1997; 72:1141–1144PubMedCrossRefGoogle Scholar
  50. 50.
    Sullivan T. Studies of the multiple drug allergy syndrome. J Allergy Clin Immunol 1989; 83:270CrossRefGoogle Scholar
  51. 51.
    Gex-Collet C, Helbling A, Pichler WJ. Multiple drug hypersensitivity—proof of multiple drug hypersensitivity by patch and lymphocyte transformation tests. J Investig Allergol Clin Immunol 2005; 15:293–296PubMedGoogle Scholar
  52. 52.
    Kanny G, Pichler W, Morisset M, Franck P, Marie B, Kohler C, Renaudin JM, Beaudouin E, Laudy JS, Moneret-Vautrin DA. T cell-mediated reactions to iodinated contrast media: evaluation by skin and lymphocyte activation tests. J Allergy Clin Immunol 2005; 115:179–185PubMedCrossRefGoogle Scholar
  53. 53.
    Castells M. Desensitization for drug allergy. Curr Opin Allergy Clin Immunol 2006; 6:476–481PubMedGoogle Scholar
  54. 54.
    Solensky R. Drug desensitization. Immunol. Allergy Clin N Am 2004; 24:425–443CrossRefGoogle Scholar
  55. 55.
    Stevenson DD. Aspirin and NSAID sensitivity. Immunol Allergy Clin N Am 2004 Aug; 24(3):491–505CrossRefGoogle Scholar

Copyright information

© Springer 2009

Authors and Affiliations

  • Benno Schnyder
    • 1
  • Werner J. Pichler
    • 1
  1. 1.Division of AllergologyClinic for Rheumatology and Clinical Immunology/ Allergology, Inselspital, University of BernSwitzerland

Personalised recommendations